STAR Ph3 Study of OP-1250 Monotherapy vs SOC for ER+ HER2 mBreast CDK4/6 (OPERA-01)
Phase III Clinical Trial
A Phase 3 Randomized Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+ HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01) (OP-1250-301)
Participating Locations